Lilly Puerto Rico plant sold to Colombia drugmaker

A surplus Eli Lilly plant in Puerto Rico has a new owner, which intends to invest more than $90 million in upgrades and hire 350 workers.

On Tuesday, Lilly ($LLY) confirmed an Associated Press report that the company sold the plant in Guayama to Bogota, Colombia-based Laboratorios Biogen SA, which is not to be confused with U.S.-based Biogen.

Biogen SA intends to invest $92 million updating the facility, where it will manufacture APIs. The company is receiving $2 million in incentives from the government for the project, Gov. Alejandro Garcia Padilla told the news service, and intends to hire 350 workers within the next 5 years.  

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Lilly announced in 2014 that it would close the plant in Guayama by the end of 2015, but was offering jobs to its 100 employees at a plant in Carolina about 50 miles away. Lilly said at the time it would take a $170 million charge to cover the costs of shuttering the Guayama facility.

The Carolina plant had benefited from $240 million in investments as part of Lilly’s buildup in insulin products. In November 2013, the facility was tagged with receiving a $200 million investment to increase its insulin API capacity and then in the next year got another $40 million for some oral solid-dosage work.

Related Articles: 
Lilly will close Puerto Rico plant, affecting 100 workers 
Lilly to invest $700M in plant expansions

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.